3Siemann DW, Bibby MC, Dark GG, et al. Differentia- tion and definition of vascular - targeted therapies [ J ]. Clin Cancer Res., 2005, 11:416-420.
4Pettit G R, Singh S B, Hamel E, et al. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A - 4 [ J ]. Experientia. , 1989, 45 (2) : 209 -211.
5Pettit G R, Singh S B, Niven M L, et al. Isolation, structure, and synthesis of combretastatin A - 1 and B - 1, potent new inhibitors of microtubule assembly, derived from Combretum Caffrum [ J ]. J. Nat. Prod. , 1987, 50 (1): 119-131.
7Bui V P, Hudlicky T, Hansen T V. et al. Direct biooxidation of arenes to corresponding catechols with E. coli JM109 (pDTG602). Application to synthesis of combretastatin A - 1 and B - 1 [ J ]. Tetrahedron Lett., 2002, 43:2839-2841.
8Odlo K, Klaveness J, Rongved P, et al Synthesis of combretastatins A - 1 and B - 1 [ J ]. Tetrahedron Lett. , 2006, 47 (7) : 1101 -1103.
9Orsini F, Pelizzoni F, Bellini B, et al. Synthesis of biologically active polyphenolic glycosides ( combret- astatin and resveratrol series) [J]. Carbohydrate Res. , 1997, 301 (3 -4) : 95 -109.
10Shirali A, Sriram M, Hall J J, et al. Development of Synthetic Methodology Suitable for the Radiosynthesis of Combretastatin A - 1 ( CA1 ) and Its Corresponding Prodrug CA1P [J]. J. Nat. Prod. , 2009, 72 (3) : 414 -421.
